Loading…
Effects of Recombinant Erythropoietin in Palliative Treatment of Unselected Cancer Patients
Purpose: The purpose is to evaluate relationships between objectively assessed exercise capacity and subjectively assessed scoring of physical functioning and well-being after erythropoietin treatment in cancer patients on palliative care. Experimental Design: Unselected cancer patients ( n = 108) w...
Saved in:
| Published in: | Clinical cancer research 2004-10, Vol.10 (20), p.6855-6864 |
|---|---|
| Main Authors: | , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c453t-eef845b060194c8f12adf440cbdc668e9f3e3027ad05b0dad25360c2872792193 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c453t-eef845b060194c8f12adf440cbdc668e9f3e3027ad05b0dad25360c2872792193 |
| container_end_page | 6864 |
| container_issue | 20 |
| container_start_page | 6855 |
| container_title | Clinical cancer research |
| container_volume | 10 |
| creator | Lindholm, Elisabet Daneryd, Peter Körner, Ulla Hyltander, Anders Fouladiun, Marita Lundholm, Kent |
| description | Purpose: The purpose is to evaluate relationships between objectively assessed exercise capacity and subjectively assessed scoring
of physical functioning and well-being after erythropoietin treatment in cancer patients on palliative care.
Experimental Design: Unselected cancer patients ( n = 108) who experienced progressive cachexia were randomized to receive either anti-inflammatory treatment alone (indomethacin)
or recombinant erythropoietin plus indomethacin to prevent the appearance of disease-induced anemia and thereby protect patients’
exercise capacity. Follow-up investigations of nutritional status, exercise capacity, and health-related quality of life assessed
by SF-36 and the European Organization for Research and Treatment of Cancer QLQ-C30 were compared.
Results: Effective treatment by erythropoietin on top of basal whole body anti-inflammatory treatment was confirmed and indicated
by time course changes of biochemical, physiologic, and nutritional objectives, whereas individual self-reported scoring of
physical functioning and general health did not indicate a clear-cut effectiveness, particularly at moderately subnormal hemoglobin
levels.
Conclusions: Discrepancies between objective and subjective self-reported measures may be either fundamental or indicate scoring limitations
for evaluation of therapeutic results. Present results demonstrate a clinical benefit of erythropoietin treatment in cancer
patients with subnormal to normal hemoglobin levels, whereas the patients’ own subjective scoring was insufficient to sense
such improvements. The discrepancy may be either fundamental or methodological but emphasizes the importance to document therapeutic
outcome in both subjective and objective perspectives in palliative care of cancer patients. |
| doi_str_mv | 10.1158/1078-0432.CCR-04-0373 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_gup_ub_gu_se_50598</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67001989</sourcerecordid><originalsourceid>FETCH-LOGICAL-c453t-eef845b060194c8f12adf440cbdc668e9f3e3027ad05b0dad25360c2872792193</originalsourceid><addsrcrecordid>eNpFkVtrFTEUhYMotlZ_gjIvCoJTc5lkMo9lOF6goJT2yYeQyeycE5mbScbSf-8ez9FCIJvk22tv1iLkNaOXjEn9kdFal7QS_LJtb7AoqajFE3LOpKxLwZV8ivU_5oy8SOknpaxitHpOzhCirFH8nPzYeQ8up2L2xQ24eezCZKdc7OJDPsR5mQPkMBV4vtthCDaH31DcRrB5BMSw625KMKAE9EVrJwcRyRzwM70kz7wdErw63Rfk7tPutv1SXn_7_LW9ui5dJUUuAbyuZEcVrlQ57Rm3va8q6rreKaWh8QIE5bXtKVK97bkUijqua143nDXignw46qZ7WNbOLDGMNj6Y2QazXxeDT_vVJDCSykYj_u6IL3H-tULKZgzJwTDYCeY1GVWjUY3edOURdHFOKYL_r8yo2UIwm8FmM9hgCFiYLQTse3MasHYj9I9dJ9cReHsCbHJ28BF9C-mRU6zhNWPIvT9yh7A_3IcIxv11OEICG91h24NTo7SU4g-W1562</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67001989</pqid></control><display><type>article</type><title>Effects of Recombinant Erythropoietin in Palliative Treatment of Unselected Cancer Patients</title><source>Freely Accessible Journals</source><creator>Lindholm, Elisabet ; Daneryd, Peter ; Körner, Ulla ; Hyltander, Anders ; Fouladiun, Marita ; Lundholm, Kent</creator><creatorcontrib>Lindholm, Elisabet ; Daneryd, Peter ; Körner, Ulla ; Hyltander, Anders ; Fouladiun, Marita ; Lundholm, Kent</creatorcontrib><description>Purpose: The purpose is to evaluate relationships between objectively assessed exercise capacity and subjectively assessed scoring
of physical functioning and well-being after erythropoietin treatment in cancer patients on palliative care.
Experimental Design: Unselected cancer patients ( n = 108) who experienced progressive cachexia were randomized to receive either anti-inflammatory treatment alone (indomethacin)
or recombinant erythropoietin plus indomethacin to prevent the appearance of disease-induced anemia and thereby protect patients’
exercise capacity. Follow-up investigations of nutritional status, exercise capacity, and health-related quality of life assessed
by SF-36 and the European Organization for Research and Treatment of Cancer QLQ-C30 were compared.
Results: Effective treatment by erythropoietin on top of basal whole body anti-inflammatory treatment was confirmed and indicated
by time course changes of biochemical, physiologic, and nutritional objectives, whereas individual self-reported scoring of
physical functioning and general health did not indicate a clear-cut effectiveness, particularly at moderately subnormal hemoglobin
levels.
Conclusions: Discrepancies between objective and subjective self-reported measures may be either fundamental or indicate scoring limitations
for evaluation of therapeutic results. Present results demonstrate a clinical benefit of erythropoietin treatment in cancer
patients with subnormal to normal hemoglobin levels, whereas the patients’ own subjective scoring was insufficient to sense
such improvements. The discrepancy may be either fundamental or methodological but emphasizes the importance to document therapeutic
outcome in both subjective and objective perspectives in palliative care of cancer patients.</description><identifier>ISSN: 1078-0432</identifier><identifier>EISSN: 1557-3265</identifier><identifier>DOI: 10.1158/1078-0432.CCR-04-0373</identifier><identifier>PMID: 15501962</identifier><language>eng</language><publisher>Philadelphia, PA: American Association for Cancer Research</publisher><subject>Administration ; Administration, Oral ; Anti-Inflammatory Agents ; Anti-Inflammatory Agents, Non-Steroidal - pharmacology ; Anti-Inflammatory Agents, Non-Steroidal - therapeutic use ; Antineoplastic agents ; Biological and medical sciences ; Cachexia ; Combination ; Drug Therapy ; Drug Therapy, Combination ; Erythropoietin ; Erythropoietin - pharmacology ; Erythropoietin - therapeutic use ; Exercise Tolerance ; Gastrointestinal Neoplasms - complications ; Gastrointestinal Neoplasms - drug therapy ; Gastrointestinal Neoplasms/complications/drug therapy ; Humans ; Indomethacin - pharmacology ; Indomethacin - therapeutic use ; Indomethacin/pharmacology/therapeutic use ; Injections ; Injections, Subcutaneous ; MEDICAL AND HEALTH SCIENCES ; Medical sciences ; MEDICIN OCH HÄLSOVETENSKAP ; Non-Steroidal/pharmacology/therapeutic use ; Nutritional Status ; Oral ; Palliative Care ; Pharmacology. Drug treatments ; Quality of Life ; Recombinant Proteins ; Recombinant/pharmacology/therapeutic use ; Reproducibility of Results ; Subcutaneous ; Tumors</subject><ispartof>Clinical cancer research, 2004-10, Vol.10 (20), p.6855-6864</ispartof><rights>2004 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c453t-eef845b060194c8f12adf440cbdc668e9f3e3027ad05b0dad25360c2872792193</citedby><cites>FETCH-LOGICAL-c453t-eef845b060194c8f12adf440cbdc668e9f3e3027ad05b0dad25360c2872792193</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27923,27924</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16192711$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15501962$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://gup.ub.gu.se/publication/50598$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Lindholm, Elisabet</creatorcontrib><creatorcontrib>Daneryd, Peter</creatorcontrib><creatorcontrib>Körner, Ulla</creatorcontrib><creatorcontrib>Hyltander, Anders</creatorcontrib><creatorcontrib>Fouladiun, Marita</creatorcontrib><creatorcontrib>Lundholm, Kent</creatorcontrib><title>Effects of Recombinant Erythropoietin in Palliative Treatment of Unselected Cancer Patients</title><title>Clinical cancer research</title><addtitle>Clin Cancer Res</addtitle><description>Purpose: The purpose is to evaluate relationships between objectively assessed exercise capacity and subjectively assessed scoring
of physical functioning and well-being after erythropoietin treatment in cancer patients on palliative care.
Experimental Design: Unselected cancer patients ( n = 108) who experienced progressive cachexia were randomized to receive either anti-inflammatory treatment alone (indomethacin)
or recombinant erythropoietin plus indomethacin to prevent the appearance of disease-induced anemia and thereby protect patients’
exercise capacity. Follow-up investigations of nutritional status, exercise capacity, and health-related quality of life assessed
by SF-36 and the European Organization for Research and Treatment of Cancer QLQ-C30 were compared.
Results: Effective treatment by erythropoietin on top of basal whole body anti-inflammatory treatment was confirmed and indicated
by time course changes of biochemical, physiologic, and nutritional objectives, whereas individual self-reported scoring of
physical functioning and general health did not indicate a clear-cut effectiveness, particularly at moderately subnormal hemoglobin
levels.
Conclusions: Discrepancies between objective and subjective self-reported measures may be either fundamental or indicate scoring limitations
for evaluation of therapeutic results. Present results demonstrate a clinical benefit of erythropoietin treatment in cancer
patients with subnormal to normal hemoglobin levels, whereas the patients’ own subjective scoring was insufficient to sense
such improvements. The discrepancy may be either fundamental or methodological but emphasizes the importance to document therapeutic
outcome in both subjective and objective perspectives in palliative care of cancer patients.</description><subject>Administration</subject><subject>Administration, Oral</subject><subject>Anti-Inflammatory Agents</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - pharmacology</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - therapeutic use</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Cachexia</subject><subject>Combination</subject><subject>Drug Therapy</subject><subject>Drug Therapy, Combination</subject><subject>Erythropoietin</subject><subject>Erythropoietin - pharmacology</subject><subject>Erythropoietin - therapeutic use</subject><subject>Exercise Tolerance</subject><subject>Gastrointestinal Neoplasms - complications</subject><subject>Gastrointestinal Neoplasms - drug therapy</subject><subject>Gastrointestinal Neoplasms/complications/drug therapy</subject><subject>Humans</subject><subject>Indomethacin - pharmacology</subject><subject>Indomethacin - therapeutic use</subject><subject>Indomethacin/pharmacology/therapeutic use</subject><subject>Injections</subject><subject>Injections, Subcutaneous</subject><subject>MEDICAL AND HEALTH SCIENCES</subject><subject>Medical sciences</subject><subject>MEDICIN OCH HÄLSOVETENSKAP</subject><subject>Non-Steroidal/pharmacology/therapeutic use</subject><subject>Nutritional Status</subject><subject>Oral</subject><subject>Palliative Care</subject><subject>Pharmacology. Drug treatments</subject><subject>Quality of Life</subject><subject>Recombinant Proteins</subject><subject>Recombinant/pharmacology/therapeutic use</subject><subject>Reproducibility of Results</subject><subject>Subcutaneous</subject><subject>Tumors</subject><issn>1078-0432</issn><issn>1557-3265</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><recordid>eNpFkVtrFTEUhYMotlZ_gjIvCoJTc5lkMo9lOF6goJT2yYeQyeycE5mbScbSf-8ez9FCIJvk22tv1iLkNaOXjEn9kdFal7QS_LJtb7AoqajFE3LOpKxLwZV8ivU_5oy8SOknpaxitHpOzhCirFH8nPzYeQ8up2L2xQ24eezCZKdc7OJDPsR5mQPkMBV4vtthCDaH31DcRrB5BMSw625KMKAE9EVrJwcRyRzwM70kz7wdErw63Rfk7tPutv1SXn_7_LW9ui5dJUUuAbyuZEcVrlQ57Rm3va8q6rreKaWh8QIE5bXtKVK97bkUijqua143nDXignw46qZ7WNbOLDGMNj6Y2QazXxeDT_vVJDCSykYj_u6IL3H-tULKZgzJwTDYCeY1GVWjUY3edOURdHFOKYL_r8yo2UIwm8FmM9hgCFiYLQTse3MasHYj9I9dJ9cReHsCbHJ28BF9C-mRU6zhNWPIvT9yh7A_3IcIxv11OEICG91h24NTo7SU4g-W1562</recordid><startdate>20041015</startdate><enddate>20041015</enddate><creator>Lindholm, Elisabet</creator><creator>Daneryd, Peter</creator><creator>Körner, Ulla</creator><creator>Hyltander, Anders</creator><creator>Fouladiun, Marita</creator><creator>Lundholm, Kent</creator><general>American Association for Cancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>F1U</scope></search><sort><creationdate>20041015</creationdate><title>Effects of Recombinant Erythropoietin in Palliative Treatment of Unselected Cancer Patients</title><author>Lindholm, Elisabet ; Daneryd, Peter ; Körner, Ulla ; Hyltander, Anders ; Fouladiun, Marita ; Lundholm, Kent</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c453t-eef845b060194c8f12adf440cbdc668e9f3e3027ad05b0dad25360c2872792193</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Administration</topic><topic>Administration, Oral</topic><topic>Anti-Inflammatory Agents</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - pharmacology</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - therapeutic use</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Cachexia</topic><topic>Combination</topic><topic>Drug Therapy</topic><topic>Drug Therapy, Combination</topic><topic>Erythropoietin</topic><topic>Erythropoietin - pharmacology</topic><topic>Erythropoietin - therapeutic use</topic><topic>Exercise Tolerance</topic><topic>Gastrointestinal Neoplasms - complications</topic><topic>Gastrointestinal Neoplasms - drug therapy</topic><topic>Gastrointestinal Neoplasms/complications/drug therapy</topic><topic>Humans</topic><topic>Indomethacin - pharmacology</topic><topic>Indomethacin - therapeutic use</topic><topic>Indomethacin/pharmacology/therapeutic use</topic><topic>Injections</topic><topic>Injections, Subcutaneous</topic><topic>MEDICAL AND HEALTH SCIENCES</topic><topic>Medical sciences</topic><topic>MEDICIN OCH HÄLSOVETENSKAP</topic><topic>Non-Steroidal/pharmacology/therapeutic use</topic><topic>Nutritional Status</topic><topic>Oral</topic><topic>Palliative Care</topic><topic>Pharmacology. Drug treatments</topic><topic>Quality of Life</topic><topic>Recombinant Proteins</topic><topic>Recombinant/pharmacology/therapeutic use</topic><topic>Reproducibility of Results</topic><topic>Subcutaneous</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lindholm, Elisabet</creatorcontrib><creatorcontrib>Daneryd, Peter</creatorcontrib><creatorcontrib>Körner, Ulla</creatorcontrib><creatorcontrib>Hyltander, Anders</creatorcontrib><creatorcontrib>Fouladiun, Marita</creatorcontrib><creatorcontrib>Lundholm, Kent</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Göteborgs universitet</collection><jtitle>Clinical cancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lindholm, Elisabet</au><au>Daneryd, Peter</au><au>Körner, Ulla</au><au>Hyltander, Anders</au><au>Fouladiun, Marita</au><au>Lundholm, Kent</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of Recombinant Erythropoietin in Palliative Treatment of Unselected Cancer Patients</atitle><jtitle>Clinical cancer research</jtitle><addtitle>Clin Cancer Res</addtitle><date>2004-10-15</date><risdate>2004</risdate><volume>10</volume><issue>20</issue><spage>6855</spage><epage>6864</epage><pages>6855-6864</pages><issn>1078-0432</issn><eissn>1557-3265</eissn><abstract>Purpose: The purpose is to evaluate relationships between objectively assessed exercise capacity and subjectively assessed scoring
of physical functioning and well-being after erythropoietin treatment in cancer patients on palliative care.
Experimental Design: Unselected cancer patients ( n = 108) who experienced progressive cachexia were randomized to receive either anti-inflammatory treatment alone (indomethacin)
or recombinant erythropoietin plus indomethacin to prevent the appearance of disease-induced anemia and thereby protect patients’
exercise capacity. Follow-up investigations of nutritional status, exercise capacity, and health-related quality of life assessed
by SF-36 and the European Organization for Research and Treatment of Cancer QLQ-C30 were compared.
Results: Effective treatment by erythropoietin on top of basal whole body anti-inflammatory treatment was confirmed and indicated
by time course changes of biochemical, physiologic, and nutritional objectives, whereas individual self-reported scoring of
physical functioning and general health did not indicate a clear-cut effectiveness, particularly at moderately subnormal hemoglobin
levels.
Conclusions: Discrepancies between objective and subjective self-reported measures may be either fundamental or indicate scoring limitations
for evaluation of therapeutic results. Present results demonstrate a clinical benefit of erythropoietin treatment in cancer
patients with subnormal to normal hemoglobin levels, whereas the patients’ own subjective scoring was insufficient to sense
such improvements. The discrepancy may be either fundamental or methodological but emphasizes the importance to document therapeutic
outcome in both subjective and objective perspectives in palliative care of cancer patients.</abstract><cop>Philadelphia, PA</cop><pub>American Association for Cancer Research</pub><pmid>15501962</pmid><doi>10.1158/1078-0432.CCR-04-0373</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1078-0432 |
| ispartof | Clinical cancer research, 2004-10, Vol.10 (20), p.6855-6864 |
| issn | 1078-0432 1557-3265 |
| language | eng |
| recordid | cdi_swepub_primary_oai_gup_ub_gu_se_50598 |
| source | Freely Accessible Journals |
| subjects | Administration Administration, Oral Anti-Inflammatory Agents Anti-Inflammatory Agents, Non-Steroidal - pharmacology Anti-Inflammatory Agents, Non-Steroidal - therapeutic use Antineoplastic agents Biological and medical sciences Cachexia Combination Drug Therapy Drug Therapy, Combination Erythropoietin Erythropoietin - pharmacology Erythropoietin - therapeutic use Exercise Tolerance Gastrointestinal Neoplasms - complications Gastrointestinal Neoplasms - drug therapy Gastrointestinal Neoplasms/complications/drug therapy Humans Indomethacin - pharmacology Indomethacin - therapeutic use Indomethacin/pharmacology/therapeutic use Injections Injections, Subcutaneous MEDICAL AND HEALTH SCIENCES Medical sciences MEDICIN OCH HÄLSOVETENSKAP Non-Steroidal/pharmacology/therapeutic use Nutritional Status Oral Palliative Care Pharmacology. Drug treatments Quality of Life Recombinant Proteins Recombinant/pharmacology/therapeutic use Reproducibility of Results Subcutaneous Tumors |
| title | Effects of Recombinant Erythropoietin in Palliative Treatment of Unselected Cancer Patients |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T12%3A37%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20Recombinant%20Erythropoietin%20in%20Palliative%20Treatment%20of%20Unselected%20Cancer%20Patients&rft.jtitle=Clinical%20cancer%20research&rft.au=Lindholm,%20Elisabet&rft.date=2004-10-15&rft.volume=10&rft.issue=20&rft.spage=6855&rft.epage=6864&rft.pages=6855-6864&rft.issn=1078-0432&rft.eissn=1557-3265&rft_id=info:doi/10.1158/1078-0432.CCR-04-0373&rft_dat=%3Cproquest_swepu%3E67001989%3C/proquest_swepu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c453t-eef845b060194c8f12adf440cbdc668e9f3e3027ad05b0dad25360c2872792193%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=67001989&rft_id=info:pmid/15501962&rfr_iscdi=true |